Perceptive Advisors - Q2 2023 holdings

$3.45 Billion is the total value of Perceptive Advisors's 95 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 40.4% .

 Value Shares↓ Weighting
FOLD  AMICUS THERAPEUTICS INC$347,446,237
+13.3%
27,662,9170.0%10.06%
+11.0%
CERE BuyCEREVEL THERAPEUTICS HLDNG I$320,709,759
+101.9%
10,088,385
+54.9%
9.28%
+97.9%
 LIANBIOsponsored ads$131,233,268
+16.3%
57,558,4510.0%3.80%
+14.0%
BuyARCELLX INC$126,998,473
+7.3%
4,016,397
+4.5%
3.68%
+5.2%
SellAMYLYX PHARMACEUTICALS INC$105,130,433
-40.6%
4,873,919
-19.2%
3.04%
-41.8%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$98,816,326
+5.4%
14,036,410
-8.5%
2.86%
+3.4%
ALDX  ALDEYRA THERAPEUTICS INC$95,227,213
-15.5%
11,350,0850.0%2.76%
-17.2%
INBX BuyINHIBRX INC$94,083,765
+37.9%
3,624,182
+0.2%
2.72%
+35.2%
VRNA BuyVERONA PHARMA PLCsponsored ads$92,955,032
+69.3%
4,397,116
+60.8%
2.69%
+66.0%
SellNUVALENT INC$92,555,602
+54.2%
2,194,821
-4.6%
2.68%
+51.2%
AKRO BuyAKERO THERAPEUTICS INC$90,610,116
+352.4%
1,940,675
+270.7%
2.62%
+343.8%
PCVX BuyVAXCYTE INC$80,609,253
+83.8%
1,614,122
+38.0%
2.33%
+80.2%
MGTX BuyMEIRAGTX HLDGS PLC$76,145,012
+111.6%
11,331,103
+62.7%
2.20%
+107.5%
APLS BuyAPELLIS PHARMACEUTICALS INC$73,976,570
+102.0%
812,037
+46.2%
2.14%
+97.9%
MDGL SellMADRIGAL PHARMACEUTICALS INC$69,989,997
-55.6%
302,987
-53.4%
2.03%
-56.5%
RETA SellREATA PHARMACEUTICALS INCcl a$68,334,204
-65.4%
670,206
-69.1%
1.98%
-66.0%
TMCI SellTREACE MED CONCEPTS INC$56,717,255
-7.8%
2,217,250
-9.2%
1.64%
-9.6%
LYRA BuyLYRA THERAPEUTICS INC$52,433,579
+185.2%
12,757,562
+39.5%
1.52%
+179.6%
VIR BuyVIR BIOTECHNOLOGY INC$48,036,216
+1351.7%
1,958,264
+1277.2%
1.39%
+1318.4%
IMVT BuyIMMUNOVANT INC$47,876,164
+138.9%
2,523,783
+95.4%
1.39%
+134.1%
XENE SellXENON PHARMACEUTICALS INC$47,100,015
-28.2%
1,223,377
-33.2%
1.36%
-29.6%
ADMA  ADMA BIOLOGICS INC$43,911,941
+11.5%
11,900,2550.0%1.27%
+9.3%
RAPT SellRAPT THERAPEUTICS INC$42,794,819
+1.8%
2,288,493
-0.1%
1.24%
-0.2%
VRDN BuyVIRIDIAN THERAPEUTICS INC$42,260,223
-4.3%
1,776,386
+2.3%
1.22%
-6.2%
MDT NewMEDTRONIC PLC$41,142,700467,000
+100.0%
1.19%
CBAY SellCYMABAY THERAPEUTICS INC$40,879,142
+20.1%
3,733,255
-4.4%
1.18%
+17.7%
PTGX BuyPROTAGONIST THERAPEUTICS INC$40,594,799
+82.9%
1,469,761
+52.3%
1.18%
+79.4%
SWTX SellSPRINGWORKS THERAPEUTICS INC$40,311,440
-24.7%
1,537,431
-26.1%
1.17%
-26.1%
IMTX  IMMATICS N.V$40,291,910
+67.2%
3,491,5000.0%1.17%
+64.0%
 ACRIVON THERAPEUTICS INC$38,981,840
+2.1%
3,007,8580.0%1.13%
+0.1%
NAUT  NAUTILUS BIOTECHNOLOGY INC$35,260,154
+39.7%
9,111,1510.0%1.02%
+37.0%
CRNX SellCRINETICS PHARMACEUTICALS IN$35,083,805
-38.5%
1,946,937
-45.2%
1.02%
-39.8%
NewDISC MEDICINE INC$32,982,007742,838
+100.0%
0.96%
BuyROIVANT SCIENCES LTD$31,567,899
+58.9%
3,131,736
+16.3%
0.91%
+55.7%
COGT BuyCOGENT BIOSCIENCES INC$31,488,125
+27.9%
2,659,470
+16.5%
0.91%
+25.3%
HRMY BuyHARMONY BIOSCIENCES HLDGS IN$31,367,310
+860.7%
891,370
+791.4%
0.91%
+845.8%
BBIO SellBRIDGEBIO PHARMA INC$30,081,647
-4.9%
1,748,933
-8.3%
0.87%
-6.7%
ESTA SellESTABLISHMENT LABS HLDGS INC$29,154,036
-8.0%
424,924
-9.2%
0.84%
-9.8%
VRCA  VERRICA PHARMACEUTICALS INC$29,074,931
-11.2%
5,038,9830.0%0.84%
-12.9%
ILMN NewILLUMINA INC$27,186,050145,000
+100.0%
0.79%
ARGX NewARGENX SEsponsored adr$26,891,37069,000
+100.0%
0.78%
MRTX SellMIRATI THERAPEUTICS INC$25,981,191
-55.6%
719,103
-54.3%
0.75%
-56.5%
RLAY  RELAY THERAPEUTICS INC$24,405,298
-23.7%
1,943,0970.0%0.71%
-25.3%
TARS  TARSUS PHARMACEUTICALS INC$23,426,237
+43.8%
1,296,4160.0%0.68%
+41.0%
RCKT BuyROCKET PHARMACEUTICALS INC$23,215,373
+56.2%
1,168,363
+34.6%
0.67%
+53.1%
BMRN SellBIOMARIN PHARMACEUTICAL INC$22,814,783
-65.1%
263,207
-60.9%
0.66%
-65.8%
SellZYMEWORKS INC$20,876,244
-31.6%
2,416,232
-28.5%
0.60%
-33.0%
CABA BuyCABALETTA BIO INC$19,945,950
+232.8%
1,545,000
+113.2%
0.58%
+226.0%
OM SellOUTSET MED INC$19,734,613
-1.6%
902,360
-17.2%
0.57%
-3.5%
NTRA SellNATERA INC$19,720,390
-49.8%
405,269
-42.7%
0.57%
-50.7%
AXSM NewAXSOME THERAPEUTICS INC$19,509,487271,493
+100.0%
0.56%
 SOLID BIOSCIENCES INC$18,318,688
+10.5%
3,495,9330.0%0.53%
+8.4%
 ASTRIA THERAPEUTICS INC$18,238,218
-37.4%
2,189,4620.0%0.53%
-38.6%
CRY SellARTIVION INC$16,009,941
+12.5%
931,352
-14.2%
0.46%
+10.2%
BMEA BuyBIOMEA FUSION INC$15,725,879
+56.0%
716,441
+120.4%
0.46%
+52.7%
ITCI NewINTRA-CELLULAR THERAPIES INC$15,564,056245,800
+100.0%
0.45%
MIRM  MIRUM PHARMACEUTICALS INC$15,562,512
+7.7%
601,5660.0%0.45%
+5.4%
TCMD SellTACTILE SYS TECHNOLOGY INC$15,017,259
+42.9%
602,377
-5.9%
0.44%
+40.3%
SellORCHESTRA BIOMED HLDGS INC$14,370,076
-67.8%
2,052,868
-9.9%
0.42%
-68.4%
ATHA  ATHIRA PHARMA INC$14,151,970
+18.0%
4,797,2780.0%0.41%
+15.8%
AXGN BuyAXOGEN INC$13,373,825
+0.4%
1,464,822
+3.9%
0.39%
-1.5%
FUSN SellFUSION PHARMACEUTICALS INC$12,849,014
+23.5%
2,751,395
-0.3%
0.37%
+21.2%
PRTA SellPROTHENA CORP PLC$12,605,512
+9.4%
184,615
-22.3%
0.36%
+7.4%
CMAX BuyCAREMAX INC$11,872,126
+24.3%
3,817,404
+6.7%
0.34%
+22.0%
NewSOLENO THERAPEUTICS INC$9,471,2602,207,753
+100.0%
0.27%
NBIX  NEUROCRINE BIOSCIENCES INC$9,434,715
-6.8%
100,0500.0%0.27%
-8.7%
TERN NewTERNS PHARMACEUTICALS INCput$9,406,2501,075,000
+100.0%
0.27%
SRPT SellSAREPTA THERAPEUTICS INC$9,284,594
-74.2%
81,074
-68.9%
0.27%
-74.7%
NewBIOHAVEN LTD$7,674,014320,820
+100.0%
0.22%
VKTX SellVIKING THERAPEUTICS INC$7,150,993
-50.7%
441,147
-49.4%
0.21%
-51.7%
XFOR SellX4 PHARMACEUTICALS INC$6,878,181
+73.9%
3,545,454
-22.0%
0.20%
+70.1%
ISEE SellIVERIC BIO INC$6,609,120
-45.7%
168,000
-66.4%
0.19%
-46.8%
NewLANDOS BIOPHARMA INC$6,255,7711,486,991
+100.0%
0.18%
SellTYRA BIOSCIENCES INC$6,130,800
-22.8%
360,000
-27.2%
0.18%
-24.7%
NBTX  NANOBIOTIXsponsored ads$5,373,186
+43.8%
1,059,8000.0%0.16%
+41.8%
NewVBI VACCINES INC CDA$4,544,6571,381,355
+100.0%
0.13%
NewACELYRIN INC$4,180,000200,000
+100.0%
0.12%
 SOMALOGIC INC$3,465,000
-9.4%
1,500,0000.0%0.10%
-11.5%
KRON  KRONOS BIO INC$3,014,721
+17.8%
1,752,7450.0%0.09%
+14.5%
QTRX  QUANTERIX CORP$2,931,500
+100.1%
130,0000.0%0.08%
+97.7%
 ENVVENO MEDICAL CORPORATION$2,407,374
-34.2%
781,6150.0%0.07%
-35.2%
OMIC SellSINGULAR GENOMICS SYSTEMS IN$1,961,468
-50.6%
2,363,214
-28.0%
0.06%
-51.3%
NewLEAP THERAPEUTICS INC$1,836,474586,733
+100.0%
0.05%
ARQT NewARCUTIS BIOTHERAPEUTICS INCput$1,417,500300,000
+100.0%
0.04%
TVTX  TRAVERE THERAPEUTICS INC$1,393,889
-31.7%
90,7480.0%0.04%
-33.3%
PNT NewPOINT BIOPHARMA GLOBAL INCput$675,000500,000
+100.0%
0.02%
VRNA NewVERONA PHARMA PLCcall$675,000500,000
+100.0%
0.02%
MRTX NewMIRATI THERAPEUTICS INCcall$690,000200,000
+100.0%
0.02%
XBI BuySPDR SER TRput$137,500
-98.2%
150,000
+50.0%
0.00%
-98.2%
VERU SellVERU INC$106,955
-97.9%
89,878
-97.9%
0.00%
-98.0%
 MOTUS GI HLDGS INC$60,318
-31.2%
90,0270.0%0.00%
-33.3%
CMAXW  CAREMAX INC*w exp 06/08/202$23,400
-19.1%
60,0000.0%0.00%0.0%
 EQRX INC*w exp 12/17/202$42,500
-1.4%
250,0000.0%0.00%0.0%
BTAI NewBIOXCEL THERAPEUTICS INCcall$10,987439,500
+100.0%
0.00%
 SURROZEN INC*w exp 08/01/203$10,000
-40.0%
166,6660.0%0.00%
ExitPEAR THERAPEUTICS INC$0-900,548
-100.0%
-0.01%
TARA ExitPROTARA THERAPEUTICS INC$0-290,051
-100.0%
-0.03%
ExitATHENEX INC$0-776,623
-100.0%
-0.03%
CLOV ExitCLOVER HEALTH INVESTMENTS CO$0-1,500,000
-100.0%
-0.04%
ExitDARIOHEALTH CORP$0-313,869
-100.0%
-0.04%
LPTX ExitLEAP THERAPEUTICS INC$0-6,726,496
-100.0%
-0.07%
ADCT ExitADC THERAPEUTICS SA$0-1,495,805
-100.0%
-0.09%
BLI ExitPHENOMEX INC$0-2,506,442
-100.0%
-0.09%
LABP ExitLANDOS BIOPHARMA INC$0-14,869,915
-100.0%
-0.13%
AVDL ExitAVADEL PHARMACEUTICALS PLCsponsored adr$0-590,000
-100.0%
-0.16%
ExitHILLEVAX INC$0-406,024
-100.0%
-0.20%
BLPH ExitBELLEROPHON THERAPEUTICS INC$0-930,000
-100.0%
-0.22%
MORF ExitMORPHIC HLDG INC$0-256,737
-100.0%
-0.28%
LRMR ExitLARIMAR THERAPEUTICS INC$0-2,280,709
-100.0%
-0.30%
ExitCYTEK BIOSCIENCES INC$0-1,289,534
-100.0%
-0.35%
ISRG ExitINTUITIVE SURGICAL INC$0-50,000
-100.0%
-0.38%
RAIN ExitRAIN ONCOLOGY INC$0-1,648,215
-100.0%
-0.42%
VBIV ExitVBI VACCINES INC CDA$0-52,335,002
-100.0%
-0.47%
TERN ExitTERNS PHARMACEUTICALS INC$0-1,350,000
-100.0%
-0.47%
BLU ExitBELLUS HEALTH INC NEW$0-4,952,538
-100.0%
-1.05%
SNY ExitSANOFIsponsored adr$0-768,101
-100.0%
-1.23%
RXDX ExitPROMETHEUS BIOSCIENCES INC$0-1,272,694
-100.0%
-4.03%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2023-08-24
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-06-07
SC 13D2024-06-06
13F-HR2024-05-15
SC 13G2024-05-13
SC 13D/A2024-05-01
SC 13D/A2024-04-17
SC 13D/A2024-04-17
42024-04-15
SC 13G/A2024-04-15
SC 13G2024-04-15

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Perceptive Advisors's holdings